<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563482</url>
  </required_header>
  <id_info>
    <org_study_id>1670</org_study_id>
    <nct_id>NCT03563482</nct_id>
  </id_info>
  <brief_title>Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy.</brief_title>
  <official_title>Correlazione Dell'Imaging Metabolico Con l'Espressione Dei Marcatori Immunitari Nei Pazienti Con NSCLC Candidati All'Immunoterapia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to prospectively investigate the correlation between the
      metabolic parameters on FDG-PET before and during immunotherapy treatment with the immune
      infiltrate and other tissue or circulating markers in a NSCLC patients candidate to
      immunotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional prospective study without medication lasting 36 months, including
      an estimated period of 18 months for the enrolment and max 18 months of follow-up. All
      consecutive patients affected by NSCLC and referred for immunotherapy with the anti-PD-1
      agent nivolumab, or other checkpoint inhibitors that may become available in the future, will
      be prospectively enrolled. The study cohort will consist of 40 patients.

      All patients will undergo the following steps: 1) selection based on eligibility criteria and
      informed consent; 2) baseline examinations (ceCT and 18F-FDG PET/CT); 3) tumor biopsy and
      blood sampling; 4) Immunotherapy with check-point inhibitors; 5) response evaluation after 8
      weeks of treatment (ceCT and 18F-FDG PET/CT) and second blood sampling; 6) follow up.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate the tumor expression of immune markers with the metabolic characteristics on FDG-PET in patients with NSCLC candidates to immunotherapy.</measure>
    <time_frame>Baseline</time_frame>
    <description>Standardized uptake value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor expression of immune markers with the metabolic characteristics on FDG-PET in patients with NSCLC candidates to immunotherapy.</measure>
    <time_frame>Before treatment</time_frame>
    <description>Metabolic tumor burden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate immune markers with the metabolic characteristics on FDG-PET in patients with NSCLC candidates to immunotherapy.</measure>
    <time_frame>Baseline</time_frame>
    <description>Tumor infiltrate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the variation of metabolic parameters on FDG-PET in patients with NSCLC before and 8 weeks after the first administration of immunotherapy.</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Standardized uptake value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantify the variation of metabolic parameters on FDG-PET in patients with NSCLC before and 8 weeks after the first administration of immunotherapy.</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Metabolic tumor burden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate other tissue or circulating markers in patients with NSCLC before and 8 weeks after the first administration of immunotherapy.</measure>
    <time_frame>Baseline</time_frame>
    <description>Tissue and blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate other tissue or circulating markers in patients with NSCLC before and 8 weeks after the first administration of immunotherapy.</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Tissue and blood samples</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlate all defined parameters with response to treatment and outcome</measure>
    <time_frame>18 months of follow up</time_frame>
    <description>Response assessment and disease outcome</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Positron-Emission Tomography</condition>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biopsy and PET scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET scan</intervention_name>
    <description>Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with pathological diagnosis of NSCLC eligible for immunotherapy;

          -  obtained informed consent.

        Exclusion Criteria:

          -  age &lt;18 years;

          -  pregnancy or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egesta Lopci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Tedeschi, MD</last_name>
    <phone>+390282241</phone>
    <email>michele.tedeschi@humanitas.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egesta Lopci, MD, PhD</last_name>
      <phone>+390282247542</phone>
      <email>egesta.lopci@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Luca Toschi, MD</last_name>
      <phone>+390282245945</phone>
      <email>luca.toschi@humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Fabio grizzi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Castello A, Grizzi F, Toschi L, Rossi S, Rahal D, Marchesi F, Russo C, Finocchiaro G, Lopci E. Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2018 Jul;39(7):636-644. doi: 10.1097/MNM.0000000000000832.</citation>
    <PMID>29608508</PMID>
  </reference>
  <reference>
    <citation>Grizzi F, Castello A, Lopci E. Is it time to change our vision of tumor metabolism prior to immunotherapy? Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1072-1075. doi: 10.1007/s00259-018-3988-1. Epub 2018 Mar 12.</citation>
    <PMID>29532102</PMID>
  </reference>
  <reference>
    <citation>Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2310-2325. doi: 10.1007/s00259-017-3802-5. Epub 2017 Aug 16. Review.</citation>
    <PMID>28815334</PMID>
  </reference>
  <reference>
    <citation>Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S, Cortese N, Qehajaj D, Pistillo D, Alloisio M, Roncalli M, Allavena P, Santoro A, Marchesi F, Chiti A. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.</citation>
    <PMID>27251642</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>June 21, 2018</last_update_submitted>
  <last_update_submitted_qc>June 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

